| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20034276 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034277 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034280 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047208 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034278 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034282 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034283 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047211 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20047209 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
| TVIS20034281 | HPV | ENSG00000179546.5 | protein_coding | HTR1D | No | No | 3352 | P28221 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HTR1D |
|---|---|
| DrugBank ID | DB00320 |
| Drug Name | Dihydroergotamine |
| Target ID | BE0000659 |
| UniProt ID | P28221 |
| Regulation Type | agonist |
| PubMed IDs | 11752352; 9605573; 1379707; 1324091; 12558771; 1407010; 14744615; 22444161; 23815106 |
| Citations | Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Lesage AS, Wouters R, Van Gompel P, Heylen L, Vanhoenacker P, Haegeman G, Luyten WH, Leysen JE: Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998 Apr;123(8):1655-65.@@Buzzi MG, Moskowitz MA: The trigemino-vascular system and migraine. Pathol Biol (Paris). 1992 Apr;40(4):313-7.@@Buzzi MG, Dimitriadou V, Theoharides TC, Moskowitz MA: 5-Hydroxytryptamine receptor agonists for the abortive treatment of vascular headaches block mast cell, endothelial and platelet activation within the rat dura mater after trigeminal stimulation. Brain Res. 1992 Jun 26;583(1-2):137-49.@@Silberstein SD, McCrory DC: Ergotamine and dihydroergotamine: history, pharmacology, and efficacy. Headache. 2003 Feb;43(2):144-66.@@Hoyer D, Lery H, Waeber C, Bruinvels AT, Nozulak J, Palacios JM: "5-HT1R" or 5-HT1D sites? Evidence for 5-HT1D binding sites in rabbit brain. Naunyn Schmiedebergs Arch Pharmacol. 1992 Sep;346(3):249-54.@@Villalon CM, Centurion D, Willems EW, Arulmani U, Saxena PR, Valdivia LF: 5-HT1B receptors and alpha 2A/2C-adrenoceptors mediate external carotid vasoconstriction to dihydroergotamine. Eur J Pharmacol. 2004 Jan 26;484(2-3):287-90.@@Dahlof C, Maassen Van Den Brink A: Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012 Apr;52(4):707-14. doi: 10.1111/j.1526-4610.2012.02124.x. Epub 2012 Mar 22.@@Ramirez Rosas MB, Labruijere S, Villalon CM, Maassen Vandenbrink A: Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs. Expert Opin Pharmacother. 2013 Aug;14(12):1599-610. doi: 10.1517/14656566.2013.806487. Epub 2013 Jul 2. |
| Groups | Approved; Investigational |
| Direct Classification | Ergotamines, dihydroergotamines, and derivatives |
| SMILES | [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O |
| Pathways | |
| PharmGKB | PA164743028 |
| ChEMBL | CHEMBL1732 |
